Drug Profile
Research programme: GlycoPEGylated erythropoietin - BioGeneriX/Neose
Alternative Names: GlycoPEG-CHO-EPOLatest Information Update: 09 Jan 2007
Price :
$50
*
At a glance
- Originator BioGeneriX; Neose Technologies
- Class
- Mechanism of Action Erythropoiesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Neutropenia
Most Recent Events
- 30 Dec 2006 Discontinued - Preclinical for Neutropenia in USA (unspecified route)
- 28 Apr 2005 Neose Technologies and BioGeneriX have entered into a research, licence and option agreement for an undisclosed protein
- 15 Feb 2005 Early research in Undefined in USA (unspecified route)